"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead
Case report
peer-reviewed

CyberKnife® Treatment of Metastatic Malignant Melanoma as Part of a Multimodality Therapy



Abstract

Metastatic malignant melanoma is an incurable disease with a median survival of 8.5 months and a probability of surviving five years after the diagnosis of less than 5%. To date, no systemic therapy has meaningfully changed these survival end points. A case of metastatic melanoma treated with combined modalities including image-guided robotic radiosurgery with CyberKnife® (Accuray Incorporated, Sunnyvale, CA, USA), and has an overall survival of 14 years is presented.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



Case report
peer-reviewed

CyberKnife® Treatment of Metastatic Malignant Melanoma as Part of a Multimodality Therapy


Author Information

William T. Brown Corresponding Author

Miami Cyberknife; University of Miami Miller School of Medicine, Miami, FL, Miami Cyberknife; University of Miami Miller School of Medicine, Miami, FL

Fahed Fayed

CyberKnife Center of Miami; Radiation Oncology Department, University of Miami Hospital & Clinics, Miami, FL

Xiaodong Wu

CyberKnife Center of Miami; University of Miami Miller School of Medicine, Miami, FL

James M. Hevezi

Austin CyberKnife Center, Austin, TX

Irene Monterroso

CyberKnife Center of Miami, Miami, FL

James G. Schwade

Cyberknife Center of Miami; Fiu Wertheim School of Medine; University of Miami Miller School of Medicine, Miami, Fl, CyberKnife Center of Miami; University of Miami Miller School of Medicine, Miami, FL

CyberKnife Center of Miami; University of Miami Miller School of Medicine, Miami, FL


Ethics Statement and Conflict of Interest Disclosures

Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

All authors contributed to drafting the manuscript and all authors reviewed and approved the final manuscript.


Case report
peer-reviewed

CyberKnife® Treatment of Metastatic Malignant Melanoma as Part of a Multimodality Therapy


Figures etc.

Share
Case report
peer-reviewed

CyberKnife® Treatment of Metastatic Malignant Melanoma as Part of a Multimodality Therapy

William T. Brown">William T. Brown , Fahed Fayed">Fahed Fayed, Xiaodong Wu">Xiaodong Wu, James M. Hevezi">James M. Hevezi, Irene Monterroso">Irene Monterroso, James G. Schwade">James G. Schwade

  • Author Information
    William T. Brown Corresponding Author

    Miami Cyberknife; University of Miami Miller School of Medicine, Miami, FL, Miami Cyberknife; University of Miami Miller School of Medicine, Miami, FL

    Fahed Fayed

    CyberKnife Center of Miami; Radiation Oncology Department, University of Miami Hospital & Clinics, Miami, FL

    Xiaodong Wu

    CyberKnife Center of Miami; University of Miami Miller School of Medicine, Miami, FL

    James M. Hevezi

    Austin CyberKnife Center, Austin, TX

    Irene Monterroso

    CyberKnife Center of Miami, Miami, FL

    James G. Schwade

    Cyberknife Center of Miami; Fiu Wertheim School of Medine; University of Miami Miller School of Medicine, Miami, Fl, CyberKnife Center of Miami; University of Miami Miller School of Medicine, Miami, FL

    CyberKnife Center of Miami; University of Miami Miller School of Medicine, Miami, FL


    Ethics Statement and Conflict of Interest Disclosures

    Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

    Acknowledgements

    All authors contributed to drafting the manuscript and all authors reviewed and approved the final manuscript.


    Article Information

    Published: May 25, 2011

    DOI

    10.7759/cureus.27

    Cite this article as:

    Brown W T, Fayed F, Wu X, et al. (May 25, 2011) CyberKnife® Treatment of Metastatic Malignant Melanoma as Part of a Multimodality Therapy. Cureus 3(5): e27. doi:10.7759/cureus.27

    Publication history

    Published: May 25, 2011

    Copyright

    © Copyright 2011
    Brown et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

    License

    This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Metastatic malignant melanoma is an incurable disease with a median survival of 8.5 months and a probability of surviving five years after the diagnosis of less than 5%. To date, no systemic therapy has meaningfully changed these survival end points. A case of metastatic melanoma treated with combined modalities including image-guided robotic radiosurgery with CyberKnife® (Accuray Incorporated, Sunnyvale, CA, USA), and has an overall survival of 14 years is presented.



Want to read more?

Create a free account to continue reading this article.

Already a member? Login.



William T. Brown, M.D.

Miami Cyberknife; University of Miami Miller School of Medicine, Miami, FL, Miami Cyberknife; University of Miami Miller School of Medicine, Miami, FL

For correspondence:
brow5417@bellsouth.net

Fahed Fayed, None

CyberKnife Center of Miami; Radiation Oncology Department, University of Miami Hospital & Clinics, Miami, FL

Xiaodong Wu, Ph.D.

CyberKnife Center of Miami; University of Miami Miller School of Medicine, Miami, FL

James M. Hevezi, Ph.D.

Austin CyberKnife Center, Austin, TX

Irene Monterroso, Ph.D.

CyberKnife Center of Miami, Miami, FL

James G. Schwade, M.D.

Cyberknife Center of Miami; Fiu Wertheim School of Medine; University of Miami Miller School of Medicine, Miami, Fl, CyberKnife Center of Miami; University of Miami Miller School of Medicine, Miami, FL

William T. Brown, M.D.

Miami Cyberknife; University of Miami Miller School of Medicine, Miami, FL, Miami Cyberknife; University of Miami Miller School of Medicine, Miami, FL

For correspondence:
brow5417@bellsouth.net

Fahed Fayed, None

CyberKnife Center of Miami; Radiation Oncology Department, University of Miami Hospital & Clinics, Miami, FL

Xiaodong Wu, Ph.D.

CyberKnife Center of Miami; University of Miami Miller School of Medicine, Miami, FL

James M. Hevezi, Ph.D.

Austin CyberKnife Center, Austin, TX

Irene Monterroso, Ph.D.

CyberKnife Center of Miami, Miami, FL

James G. Schwade, M.D.

Cyberknife Center of Miami; Fiu Wertheim School of Medine; University of Miami Miller School of Medicine, Miami, Fl, CyberKnife Center of Miami; University of Miami Miller School of Medicine, Miami, FL